In the future, this issue may also be addressed by the enrolment of patients with these small cancers into clinical trials designed to confirm the prognostic impact of HER2 status and the benefits of adjuvant Trastuzumab within the different hormone receptor groups, tumour grades, and proliferative indices (Joerger et al, 2011). This evidence concerns the gene ERBB2 and cancer.